Adage Capital Partners’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $41.2M | Buy |
2,784,000
+599,102
| +27% | +$8.87M | 0.07% | 279 |
|
|
2025
Q1 | $39.2M | Buy |
2,184,898
+1,808,098
| +480% | +$32.4M | 0.07% | 281 |
|
|
2024
Q4 | $6.56M | Sell |
376,800
-23,200
| -6% | -$404K | 0.01% | 681 |
|
|
2024
Q3 | $5.6M | Hold |
400,000
| – | – | 0.01% | 704 |
|
|
2024
Q2 | $3.29M | Sell |
400,000
-100,000
| -20% | -$822K | 0.01% | 749 |
|
|
2024
Q1 | $3.86M | Hold |
500,000
| – | – | 0.01% | 721 |
|
|
2023
Q4 | $4.5M | Buy |
+500,000
| New | +$4.5M | 0.01% | 690 |
|
|
2023
Q2 | – | Sell |
-4,113,962
| Closed | -$92.5M | – | 930 |
|
|
2023
Q1 | $92.5M | Buy |
4,113,962
+1,513,962
| +58% | +$34M | 0.21% | 116 |
|
|
2022
Q4 | $54.7M | Buy |
2,600,000
+250,000
| +11% | +$5.26M | 0.13% | 190 |
|
|
2022
Q3 | $57.9M | Buy |
2,350,000
+400,000
| +21% | +$9.86M | 0.14% | 162 |
|
|
2022
Q2 | $47.2M | Buy |
1,950,000
+447,508
| +30% | +$10.8M | 0.11% | 200 |
|
|
2022
Q1 | $38.7M | Buy |
1,502,492
+200,000
| +15% | +$5.15M | 0.07% | 285 |
|
|
2021
Q4 | $40.4M | Sell |
1,302,492
-397,508
| -23% | -$12.3M | 0.07% | 279 |
|
|
2021
Q3 | $41.2M | Sell |
1,700,000
-1,893,763
| -53% | -$45.9M | 0.08% | 250 |
|
|
2021
Q2 | $52.4M | Sell |
3,593,763
-956,237
| -21% | -$14M | 0.1% | 205 |
|
|
2021
Q1 | $114M | Buy |
4,550,000
+1,700,000
| +60% | +$42.4M | 0.23% | 91 |
|
|
2020
Q4 | $77.7M | Buy |
2,850,000
+1,315,500
| +86% | +$35.9M | 0.17% | 131 |
|
|
2020
Q3 | $28.3M | Sell |
1,534,500
-100,000
| -6% | -$1.85M | 0.07% | 293 |
|
|
2020
Q2 | $33.4M | Buy |
1,634,500
+592,702
| +57% | +$12.1M | 0.09% | 266 |
|
|
2020
Q1 | $15.2M | Buy |
1,041,798
+966,798
| +1,289% | +$14.1M | 0.05% | 384 |
|
|
2019
Q4 | $1.07M | Sell |
75,000
-25,000
| -25% | -$355K | ﹤0.01% | 679 |
|
|
2019
Q3 | $1.16M | Buy |
+100,000
| New | +$1.16M | ﹤0.01% | 678 |
|